- Home
- JOYY vs ACAD Comparison
JOYY vs ACAD Comparison
Compare JOYY & ACAD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- JOYY
- ACAD
- Stock Information
- Founded
- JOYY 2005
- ACAD 1993
- Country
- JOYY Singapore
- ACAD United States
- Employees
- JOYY N/A
- ACAD N/A
- Industry
- JOYY
- ACAD Biotechnology: Pharmaceutical Preparations
- Sector
- JOYY
- ACAD Health Care
- Exchange
- JOYY NYSE
- ACAD Nasdaq
- Market Cap
- JOYY 2.2B
- ACAD 2.5B
- IPO Year
- JOYY N/A
- ACAD 2004
- Fundamental
- Price
- JOYY $47.88
- ACAD $21.57
- Analyst Decision
- JOYY
- ACAD Buy
- Analyst Count
- JOYY 0
- ACAD 14
- Target Price
- JOYY N/A
- ACAD $27.08
- AVG Volume (30 Days)
- JOYY 325.7K
- ACAD 3.0M
- Earning Date
- JOYY 05-26-2025
- ACAD 05-07-2025
- Dividend Yield
- JOYY 3.90%
- ACAD N/A
- EPS Growth
- JOYY 501.96
- ACAD N/A
- EPS
- JOYY 31.00
- ACAD 1.37
- Revenue
- JOYY $2,167,579,000.00
- ACAD $996,283,000.00
- Revenue This Year
- JOYY N/A
- ACAD $13.49
- Revenue Next Year
- JOYY $5.31
- ACAD $10.58
- P/E Ratio
- JOYY $1.54
- ACAD $15.76
- Revenue Growth
- JOYY N/A
- ACAD 22.42
- 52 Week Low
- JOYY $27.88
- ACAD $13.40
- 52 Week High
- JOYY $55.31
- ACAD $25.23
- Technical
- Relative Strength Index (RSI)
- JOYY N/A
- ACAD 68.70
- Support Level
- JOYY N/A
- ACAD $21.95
- Resistance Level
- JOYY N/A
- ACAD $22.62
- Average True Range (ATR)
- JOYY 0.00
- ACAD 1.21
- MACD
- JOYY 0.00
- ACAD 0.23
- Stochastic Oscillator
- JOYY 0.00
- ACAD 56.27
About JOYY JOYY INC SPON ADS EACH REP 20 ORD SHS CL A
JOYY Inc is a technology company. The Company operates several social products, including Bigo Live for live streaming, Likee for short-form videos, Hago for multiplayer social networking, an instant messaging product, and others. The Company operates through two segments: BIGO and All other. The BIGO segment consists of several social entertainment platforms, including Bigo Live, Likee, imo, and others. The All other segment consist of Hago, Shopline, and certain audio live streaming platforms.
About ACAD ACADIA Pharmaceuticals Inc.
Acadia Pharmaceuticals Inc is a biopharmaceutical company focused on the development and commercialization of medicines that address unmet medical needs in central nervous system (CNS) disorders and rare diseases. It has two core franchises in neuroscience and neuro-rare diseases. The neuroscience franchise is anchored by its commercial product NUPLAZID (pimavanserin), which is used for the treatment of hallucinations and delusions associated with Parkinson's Disease Psychosis (PDP). The neuro-rare disease franchise is anchored by the commercial product DAYBUE, which is used for the treatment of Rett syndrome. In addition, the company has various product candidates under development in different stages, including ACP-204, ACP-101, ACP-211, ACP-711, ACP-2591, etc.